CD8A and neoplasm: In syngeneic models, treatment promoted CD8<sup>+</sup> cytotoxic T cell-dependent anti-tumour responses and reduced immunosuppressive signalling within the TIME.<h4>Conclusions</h4>CHK1i+LDHU is a promising therapy for chemotherapy-resistant HGSOC, combining direct cytotoxic effects with reprogramming the TIME to reduce immunosuppression and activate a CD8<sup>+</sup> T cell-dependent anti-tumour response.